NCT00062296View on ClinicalTrials.gov

Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions
LeukemiaLymphoma
Interventions
BIOLOGICAL

rituximab

DRUG

epirubicin hydrochloride

Trial Locations (1)

19111

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fox Chase Cancer Center

OTHER

NCT00062296 - Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter